Trial Profile
Pharmacokinetics of Lenalidomide (Revlimid) in Patients With Multiple Myeloma and Impaired Renal Function.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Oct 2016 Status changed from recruiting to completed.
- 16 Feb 2009 Actual initiation date (Nov 2008) added as reported by ClinicalTrials.gov.
- 16 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.